Loading
Immune Cells in Cancer / Ferroptosis and Cancer Prognosis · Journal article
Proceedings of the National Academy of Sciences · August 10, 2026
Encouraging direction, but not yet definitive.
Single-cell multiomics reveals ALDH9A1 as a driver of anti-PD-1 resistance in NSCLC through carnitine-dependent IL-1β activation and MDSC expansion. In immunocompetent mouse models, ALDH9A1 loss or pharmacological inhibition restores immunotherapy sensitivity; this axis is hyperactivated in NSCLC patients and correlates with inferior anti-PD-1 responses, but clinical efficacy has not been tested.
Preclinical mechanistic study with correlative human data. NSCLC tumors for omics analysis; immunocompetent and immunocompromised mouse models; NSCLC patients for biomarker correlation. Intervention: ALDH9A1 genetic loss, pharmacological ALDH9A1 inhibition, or antibody-mediated IL-1β neutralization. Compared with: Wild-type or control-treated mice; anti-PD-1 therapy alone versus combined with ALDH9A1 or IL-1β inhibition.
ALDH9A1 loss markedly restrains tumor growth in immunocompetent mouse models ALDH9A1 inhibition accompanied by increased tertiary lymphoid structure maturation and reduced protumorigenic MDSC accumulation ALDH9A1-driven carnitine production elevates acetyl-CoA, remodels chromatin, and activates Il1b superenhancers in tumor cells
Genetic or pharmacological ALDH9A1 inhibition, or IL-1β neutralization, suppresses tumor progression and restores anti-PD-1 sensitivity in vivo
Identifies ALDH9A1 as a potential therapeutic target to overcome anti-PD-1 resistance in NSCLC, with early evidence of biomarker utility. Clinical trials are needed to validate whether ALDH9A1 inhibition improves patient outcomes.
Mechanistic discovery in preclinical models with supporting human correlative data, but lacks clinical trial evidence of efficacy in patients with immunotherapy resistance.
As stated by the source record.
Identifies ALDH9A1 as a potential therapeutic target to overcome anti-PD-1 resistance in NSCLC, with early evidence of biomarker utility. Clinical trials are needed to validate whether ALDH9A1 inhibition improves patient outcomes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Immunotherapy resistance remains a major barrier to achieving sustained patient improvement in non–small cell lung cancer (NSCLCs). Here, through integrating CODEX, metabolomics, CyTOF, ATAC-seq, and single-cell spatial transcriptomics from NSCLC tumors, we uncover an unrecognized role of ALDH9A1 in promoting resistance to anti-PD-1 therapy. In immunocompetent, but not immunocompromised mouse models, loss of ALDH9A1 markedly restrains tumor growth. This effect is accompanied by increased maturation of tertiary lymphoid structures and reduced accumulation of protumorigenic MDSCs within tumor immune microenvironment. Mechanistically, ALDH9A1-driven carnitine production elevates acetyl-CoA levels, remodels chromatin accessibility, and activates Il1b superenhancers in tumor cells, thereby promoting MDSC polarization and CD8 + T cell exhaustion. In vivo, genetic or pharmacological inhibition of ALDH9A1, or antibody-mediated IL-1β neutralization, suppresses tumor progression and restores sensitivity to anti-PD-1 therapy. IL-1β further activates NF-κB and upregulates ALDH9A1, establishing a feedback ALDH9A1-IL-1β loop. Importantly, the ALDH9A1/IL-1β axis is frequently hyperactivated in NSCLC patients and correlates with inferior responses to anti-PD-1 immunotherapy. Together, this study reveals a previously unappreciated NSCLC-specific immunoregulatory pathway and identifies ALDH9A1 as a promising therapeutic target for improving immunotherapy efficacy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.